Cardiovascular and metabolic market overview forecast model

Introduction

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2018. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Reasons to Purchase

• Qualify and quantify the Top 10 cardiovascular therapy brands across the seven major pharmaceutical markets from 2008 to 2018.
• Understand key drivers and predict the future performance of leading products.
• Assess the remaining market opportunities, where established therapies and other developmental compounds fail to address key unmet clinical needs.

View Table Of Contents >